<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In Epstein-Barr virus (EBV)-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, the virus is harbored in every <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell and persists in tightly latent forms expressing a very limited number of <z:mp ids='MP_0001799'>viral</z:mp> latent proteins </plain></SENT>
<SENT sid="1" pm="."><plain>Induction of EBV lytic cycle leads to expression of a much larger number of <z:mp ids='MP_0001799'>viral</z:mp> proteins, which may serve as potential therapeutic targets </plain></SENT>
<SENT sid="2" pm="."><plain>We found that 4 histone deacetylase inhibitors, <z:chebi fb="0" ids="46024">trichostatin A</z:chebi> (TSA), <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> (SB), <z:chebi fb="0" ids="39867">valproic acid</z:chebi> (VPA) and suberoylanilide <z:chebi fb="0" ids="24650">hydroxamic acid</z:chebi> (SAHA), <z:hpo ids='HP_0000001'>all</z:hpo> significantly induced EBV lytic cycle in EBV-positive gastric <z:mp ids='MP_0002038'>carcinoma</z:mp> cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>/BX1, latency II) but only weakly induced in Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells (AK2003, latency I) and did not induce in lymphoblastoid cells (LCLs, latency III) </plain></SENT>
<SENT sid="3" pm="."><plain>Interestingly, SAHA potently induced <z:mp ids='MP_0001799'>viral</z:mp> lytic cycle in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>/BX1 cells at micromolar concentrations (evidenced by 8-fold increase in <z:mp ids='MP_0001799'>viral</z:mp> DNA replication, strong expression of <z:mp ids='MP_0001799'>viral</z:mp> lytic proteins and production of infectious virus particles) and mediated enhanced cell <z:hpo ids='HP_0011420'>death</z:hpo> of EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>/BX1 cells when compared with that of EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> cells, possibly related to cell cycle arrest at G2/M phase </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, SAHA effected strong induction of EBV lytic cycle in nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> but not in NK <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells (both expressing EBV latency II pattern), indicating preferential <z:mp ids='MP_0001799'>viral</z:mp> lytic induction in epithelial rather than lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, SAHA is found to be a potent EBV lytic cycle inducing agent, which warrants further investigation into its potential application as a novel virus-targeted drug for treatment of EBV-associated epithelial <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>